Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

The collaboration marks the first time patients using LillyDirect, Lilly’s direct-to-consumer healthcare platform can access self-pay pricing for Zepbound vials at a retail pharmacy location.

Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

Lilly shares are up about 5% this year. Compared with its peers, the drugmaker has been more insulated from drug price ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly and Company and Walmart Inc. announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect. Zepbound ...

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...